EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer

Tomonari Kinoshita, Shigeki Ohta, Seiki Wakui, Chihaya Maeda, Yuichiro Hayashi, Aya Misawa, Ryosuke Satomi, Shinnosuke Ikemura, Kenzo Soejima, Tomonori Yaguchi iD, Shotaro Maruyama, Hiroshi Kagamu und 1 weitere

Cancer Science · 2026-08 · 117 (8) · 2152-2165

DOI: 10.1111/cas.70412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 24.05.2026. Verfasst von Tomonari Kinoshita und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Extracellular Vesicles, Programmed Cell Death 1 Receptor. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Grants-in-aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy is a promising biomarker for cancer detection and prediction of therapy responses. In this study, we developed new antibody‐based sandwich assays to measure three extracellular vesicle (EV) subsets that express cell surface vimentin (CSV) and co‐express epithelial cell adhesion molecule (EpCAM) or PD‐L1 in plasma. Fifty‐seven non‐small cell lung cancer (NSCLC) patients who underwent complete resection and 89 stage IV NSCLC patients who received anti‐PD‐1 antibody were enrolled. Correlations between the plasma EV subsets at baseline and various clinicopathological factors were evaluated. Plasma EpCAM/CSV‐EV levels were significantly higher in stage I NSCLC patients compared to healthy donors, suggesting this may be a valuable biomarker for detecting early‐stage NSCLC. High plasma CSV/CSV‐EV levels at baseline were significantly correlated with a poor prognosis after treatment, both in the surgery cohort and the anti‐PD‐1 antibody cohort, which suggests that this may be useful for predicting the post‐treatment prognosis in NSCLC patients. High plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with poor postoperative prognosis. However, high plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with a favorable clinical response and prognosis following anti‐PD‐1 antibody treatment in stage IV NSCLC. Therefore, plasma CSV‐related EV subsets at baseline may be attractive biomarkers for early cancer detection (EpCAM/CSV), prediction of postoperative prognosis (CSV/CSV), and prediction of clinical responses and prognosis after anti‐PD‐1 antibody therapy (CSV/PD‐L1). These EV subsets can be easily measured repetitively at appropriate timing. These novel liquid biopsies may be additional and complementary diagnostic biomarkers for NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsExtracellular VesiclesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansFemaleMaleBiomarkers, TumorEpithelial Cell Adhesion MoleculePrognosisMiddle AgedAgedB7-H1 AntigenVimentinAdultNeoplasm StagingLiquid Biopsy

Stichwörter der Autor:innen

CSVEpCAMPD‐L1biomarkerextracellular vesiclenon‐small cell lung cancer

Substanzen

Biomarkers, TumorEpithelial Cell Adhesion MoleculeProgrammed Cell Death 1 ReceptorB7-H1 AntigenVimentinEPCAM protein, humanCD274 protein, humanPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of General Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
  • Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
  • Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan.
  • JSR-Keio University Medical and Chemical Innovation Center (JKiC), Tokyo, Japan.
  • Division of Pathology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Pathology, International University of Health and Welfare, Narita Hospital, Chiba, Japan.

ORCID-Profile: Tomonori Yaguchi, Yutaka Kawakami

Förderung

  • Japan Agency for Medical Research and Development
  • Grants-in-aid for Scientific Research

Zitieren

APA

Kinoshita, T., Ohta, S., Wakui, S., Maeda, C., Hayashi, Y., Misawa, A., Satomi, R., Ikemura, S., Soejima, K., Yaguchi, T., Maruyama, S., Kagamu, H., & Kawakami, Y. (2026). Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer. Cancer Science, 117(8), 2152-2165. https://doi.org/10.1111/cas.70412

Vancouver

Kinoshita T, Ohta S, Wakui S, Maeda C, Hayashi Y, Misawa A, et al. Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer. Cancer Science. 2026;117(8):2152-2165. doi:10.1111/cas.70412

BibTeX
@article{Kinoshita2026,
  author = {Kinoshita, Tomonari and Ohta, Shigeki and Wakui, Seiki and Maeda, Chihaya and Hayashi, Yuichiro and Misawa, Aya and Satomi, Ryosuke and Ikemura, Shinnosuke and Soejima, Kenzo and Yaguchi, Tomonori and Maruyama, Shotaro and Kagamu, Hiroshi and Kawakami, Yutaka},
  title = {Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {8},
  pages = {2152--2165},
  doi = {10.1111/cas.70412}
}
Kostenlos starten →